[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100640432":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":30,"centralContacts":35,"locations":45,"responsibleParty":66,"collaborators":71,"id":76,"slug":77,"hasResults":78,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":78,"sex":84,"minAge":85,"maxAge":25,"enrollmentInfo":86,"targetDuration":25,"studyType":89,"phases":90,"briefSummary":92,"conditions":93,"keywords":95,"overallStatus":48,"whyStopped":25,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":109},{"fullName":5,"class":6},"Hospital Ambroise Paré Paris","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"capsaicin 8%","ACTIVE_COMPARATOR","The minimum time between 2 applications of capsaicin is 60 days, but this could be adapted to the patients' response and therefore could be longer (up to 3 months). Thus, skin biopsies will be performed before the first capsaicin application and before the third application, that is to say 4 to 6 months after the first application. Patients will continue then to be followed for up to one year and another skin punch biopsy will be performed after the fifth 8% capsaicin application (i.e. 8 to 12 months after the first application).",[13],"Drug: Capsaicin 8% Patch",{"label":15,"type":10,"description":16,"interventionNames":17},"other treatments","Other treatments for neuropathic pain include antidepressants (tricyclics and serotonin reuptake inhibitor SRIs), antiepiletics, lidocaine patches, and neurostimulation according to the 2020 French recommendations.",[18],"Drug: antidepressants (tricyclics and serotonin reuptake inhibitor SRIs), antiepiletics, lidocaine patches, and neurostimulation",[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Capsaicin 8% Patch","The hypothesis is that in the chronic phase, in the absence in the nervous environment of the toxic agent (in this case taxanes) causing the neuropathy and the functional modifications at the origin of pain, the new small fibers could regenerate without these pathological alterations (in particular the changes in the membrane excitability responsible for pain). Thus, capsaicin could, in this specific clinical context, have a \"curative\" effect on neuropathic pain. However, since the action of capsaicin only concerns small fibers, one cannot expect a global improvement of the neuropathy, which affects all the fibers",[9],null,{"type":21,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"antidepressants (tricyclics and serotonin reuptake inhibitor SRIs), antiepiletics, lidocaine patches, and neurostimulation","These treatments are administered to patients according to the French recommendations on the management of neuropathic pain from 2020.",[15],[31],{"name":32,"affiliation":33,"role":34},"Didier BOUHASSIRA, MD, PhD","Institut National de la Santé Et de la Recherche Médicale, France","STUDY_DIRECTOR",[36,40],{"name":32,"role":37,"phone":38,"phoneExt":25,"email":39},"CONTACT","0033149094556","didier.bouhassira@inserm.fr",{"name":41,"role":37,"phone":42,"phoneExt":43,"email":44},"Marie PECHARD, MD","0033147111515","3683","marie.pechard@curie.fr",[46],{"facility":47,"status":48,"city":49,"state":50,"zip":51,"country":52,"countryCode":53,"cosmosGeoPoint":54,"geoPoint":59,"contacts":60},"Inserm U987","RECRUITING","Boulogne-Billancourt","HAUTS DE SEINE","92100","France","FR",{"type":55,"coordinates":56},"Point",[57,58],2.24128,48.83545,{"lat":58,"lon":57},[61,64],{"name":62,"role":37,"phone":63,"phoneExt":25,"email":44},"MARIE PECHARD, MD","0033149095946",{"name":65,"role":37,"phone":38,"phoneExt":25,"email":39},"Didier BOUHASSIRA, MD PHD",{"type":67,"investigatorFullName":68,"investigatorTitle":69,"investigatorAffiliation":70,"oldNameTitle":25,"oldOrganization":25},"PRINCIPAL_INVESTIGATOR","Marie PECHARD","MD","Institut Curie",[72,73],{"name":70,"class":6},{"name":74,"class":75},"Grünenthal GmbH","INDUSTRY","100640432","chemotherapy-induced-peripheral-neuropathy-by-taxanes-and-capsaicin-8-100640432",false,"NCT07602387","Chemotherapy Induced Peripheral Neuropathy by Taxanes and Capsaicin 8%.","Chemotherapy Induced Peripheral Neuropathy by Taxanes: Pathophysiological Evolution and Somatosensory Response Profile to Capsaicin 8%.","capsaNeP","Inclusion Criteria:\n\n* patients over 18 years of age with no age limit\n* having given their signed consent for participation in the study\n* affiliated with the social security system\n* able to be followed for the entire duration of the study\n* reading and understanding French\n* accepting the principle of the study and able to respect its conditions\n* presenting sensorimotor or sensory neuropathy induced by taxanes (paclitaxel or docetaxel) of the lower limbs for at least 3 months based on a complete clinical examination, the severity of which will be assessed by the NCI-CTCAE version 5 criteria (grade 2 to 4). An electromyogram (EMG) will be performed in the absence of a recent electromyogram (less than one year) to assess the function of large fibers, but its normality will not constitute an exclusion criterion (due to the possibility of chemotherapy-induced small fiber neuropathies).\n* presenting chronic neuropathic pain in the lower limbs for at least 3 months, with a DN4 questionnaire score ≥ 4\u002F10 and of at least moderate intensity on an 11-point numerical scale (≥ 4\u002F10)\n* whose pain is located in the lower limbs allowing the application of 8% capsaicin\n* without treatment or having stable analgesic treatment for at least 2 weeks before inclusion\n\nExclusion Criteria:\n\n* litigation or compensation-seeking\n* metastatic cancer\n* Known cause of sensory neuropathy such as diabetes, systemic disease, hypothyroidism, alcohol, kidney failure, or genetic disease\n* Peripheral or central nervous system pathology with or without associated neuropathic pain\n* Uncontrolled chronic pathology such as morbid obesity, sleep apnea, uncontrolled hypertension, etc.\n* Psychosis, previous suicide attempt, or major depressive episode at the time of assessment\n* Drug or psychoactive substance abuse\n* Cognitive or psychological disorders incompatible with compliance with and\u002For understanding of the protocol\n* Patients participating in another biomedical research protocol\n* Contraindications to confocal corneal microscopy, including the wearing of long-term contact lenses or ocular procedures (eye surgery, laser for myopia, dry eye).\n* Pregnant or breastfeeding women\n* Persons under legal protection","ALL","18 Years",{"count":87,"type":88},50,"ESTIMATED","INTERVENTIONAL",[91],"NA","The goal of this study is to compare the evolution of the density of small nerve fibers assessed with skin biopsies at the foot between two groups of patients with taxane-induced chronic neuropathic pain matched for sex and age: one group treated with applications of capsaicin 8% and a control group who received a systemic treatment. The hypothesis for the capsaicin 8% arm is that in the chronic phase, in the absence in the nervous environment of the toxic agent (in this case taxanes) causing the neuropathy and the functional modifications at the origin of pain, the new small fibers could regenerate without these pathological alterations.\n\nOur analysis will be based on the demonstration of structural abnormalities of small nerve fibers by means of skin biopsy, but also of functional abnormalities using four validated tests commonly used in this field: quantitative sensory testing (QST), laser evoked potential recordings, Sudoscan and confocal corneal microscopy.",[94],"Patients With Taxane-induced Chronic Neuropathic Pain",[96,97,98,99],"chronic neuropathic pain","taxanes","moderate to severe pain","skin biopsy","2026-05-18",{"date":102,"type":103},"2026-05-22","ACTUAL",{"date":105,"type":103},"2024-03-12",{"date":107,"type":88},"2028-03",{"name":5,"class":6},1]